FY2024 Earnings Estimate for PVLA Issued By HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA) – Equities researchers at HC Wainwright issued their FY2024 earnings per share estimates for shares of Palvella Therapeutics in a research note issued on Thursday, December 26th. HC Wainwright analyst A. Fein expects that the company will earn ($4.37) per share for the year. HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock.

Separately, Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA opened at $12.00 on Monday. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $22.32. The firm has a market cap of $15.84 million, a PE ratio of -0.99 and a beta of 0.61.

Insider Activity

In other Palvella Therapeutics news, Director George M. Jenkins purchased 4,000 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was purchased at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.39% of the company’s stock.